Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Other Accumulated Expenses (2019 - 2025)

Historic Other Accumulated Expenses for China Pharma Holdings (CPHI) over the last 7 years, with Q3 2025 value amounting to $1.6 million.

  • China Pharma Holdings' Other Accumulated Expenses rose 661460.83% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 661460.83%. This contributed to the annual value of $1.6 million for FY2024, which is 2644.35% up from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Other Accumulated Expenses is $1.6 million, which was up 661460.83% from $1.6 million recorded in Q2 2025.
  • China Pharma Holdings' Other Accumulated Expenses' 5-year high stood at $3.1 million during Q3 2021, with a 5-year trough of $24000.0 in Q3 2024.
  • In the last 5 years, China Pharma Holdings' Other Accumulated Expenses had a median value of $2.4 million in 2022 and averaged $2.0 million.
  • As far as peak fluctuations go, China Pharma Holdings' Other Accumulated Expenses plummeted by 9783.68% in 2024, and later soared by 661460.83% in 2025.
  • China Pharma Holdings' Other Accumulated Expenses (Quarter) stood at $2.8 million in 2021, then dropped by 10.93% to $2.5 million in 2022, then tumbled by 49.29% to $1.3 million in 2023, then increased by 26.44% to $1.6 million in 2024, then grew by 1.51% to $1.6 million in 2025.
  • Its Other Accumulated Expenses was $1.6 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.6 million in Q1 2025.